Five-year clinical outcomes after coronary stenting of chronic total occlusion using XXXX -eluting stents: insights from the @entity3446 -eluting stent evaluated at Rotterdam Cardiology Hospital-(Research) Registry.

@entity1 @entity75 @entity3446 @entity583 @entity204
BACKGROUND: The use of drug eluting stents (DES) in @entity1 with a successfully recanalized chronic total occlusion (CTO) has been associated with a significant decrease in the need for repeat revascularization, and a favorable short-term clinical outcome when compared with the use of bare metal stents (BMS). Our group, however, has previously reported similar rates of @entity75 revascularisation (TLR) and major adverse cardiovascular events (MACE) at 3 years follow-up in @entity1 with a successfully opened CTO who were treated with either a @entity3446 eluting stent (SES) or a BMS. The objective of this report was to evaluate the outcomes of these @entity1 at 5-years clinical follow-up. METHODS AND RESULTS: A total of 140 (BMS 64, SES 76) @entity1 with successfully opened CTOs were included. Seven @entity1 died in the BMS group whilst nine @entity1 died in the SES group (P = 0.90). @entity204 was the major component of all-cause mortality (11 noncardiac deaths vs. 5 cardiac). There were two and three @entity583 ( @entity583 ) in the BMS and SES group, respectively (P = 1.0). The composite of @entity204 and @entity583 occurred in seven (10.9%) and eleven (14.5%) @entity1 in the BMS and SES group, respectively (P = 0.53). Clinically driven TLR was performed in eight @entity1 (12.5%) in the BMS group, and five (6.6%) in the SES group (P = 0.26). Non-TLR target vessel revascularization was performed in one @entity1 in the BMS group, and four in the SES group (P = 0.37). The 5-year device-oriented cumulative MACE rate was 15.6% and 11.8% in the BMS and SES group, respectively (P = 0.56). CONCLUSION: In @entity1 with a successfully treated CTO, clinical outcome after 5 years was similar between SES and BMS, however, clinically driven TLR was slightly higher in the BMS group.
